Trial Shows Micardis - Read More |
| Date Added: September 01, 2008 09:44:04 PM |
| The results of the TRANSCEND® trial demonstrate that Micardis® 80mg (telmisartan) reduces the risk of cardiovascular death, myocardial infarction/heart attack and stroke in high-risk cardiovascular patients by 13% compared with those patients already receiving best standard of care (p=0. |
No comments are posted yet |
Related Articles
|


























